Uncategorized

ANZGOG welcomes the Australian Government’s support to accelerate gynaecological cancer clinical trials.

  The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is thrilled to announce it has been awarded $1.58 million over three years (2024-2027) as part of the Australian Government’s $22.19 million investment in cancer clinical trials through the Support [...]

ANZGOG welcomes the Australian Government’s support to accelerate gynaecological cancer clinical trials.2024-11-08T15:22:31+11:00

RAMP 301 trial investigates treatment for a rare subtype of ovarian cancer – low grade serous ovarian cancer

RAMP 301 (VS-6766-301/GOG-3097/ENGOT-ov81) is a Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC). We’re excited to announce [...]

RAMP 301 trial investigates treatment for a rare subtype of ovarian cancer – low grade serous ovarian cancer2025-07-22T16:10:28+10:00

New Position Statement provides important guidance on testing for ovarian cancer in asymptomatic women

Cancer Australia has released an updated Position Statement - Testing for ovarian cancer in asymptomatic women. The Position Statement provides health professionals with up-to-date evidence-based information and guidance in relation to routine screening of women who [...]

New Position Statement provides important guidance on testing for ovarian cancer in asymptomatic women2020-10-07T03:49:04+11:00

2019 ASM – Round-up

The 2019 Annual Scientific Meeting took place at the Sofitel Sydney Wentworth from 20th to 23rd March, inspired by the theme ‘Radical Treatments for Gynaecological Cancers: hope or hype’.  With 260 delegates, this was the [...]

2019 ASM – Round-up2020-03-10T05:27:25+11:00
Go to Top